Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients

British Journal of Haematology

Volumn 151, Issue 5, 2010, Pages 509-515

  Rigano, Paolo ^a   Pecoraro, Alice ^a   Calzolari, Roberta ^a   Troia, Antonio ^a   Acuto, Santina ^a   Renda, Disma ^a   Pantalone, Gaetano Restivo ^a   Maggio, Aurelio ^a   Marzo, Rosalba Di ^a  

^a Ospedali Riuniti Villa Sofia Cervello   (Italy)

Author keywords

Fetal haemoglobin; HBG mRNA; Hydroxycarbamide; Primary erythroid cultures; Thalassaemia intermedia

Indexed keywords

HYDROXYUREA;

ADULT; ARTICLE; BETA THALASSEMIA; CELL CULTURE; CLINICAL ARTICLE; DESENSITIZATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERYTHROID CELL; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; IN VIVO STUDY; LONG TERM CARE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CELLS, CULTURED; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; FEMALE; FETAL HEMOGLOBIN; FOLLOW-UP STUDIES; GENOTYPE; HEMATOPOIESIS, EXTRAMEDULLARY; HEMOGLOBINS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78349279577     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08397.x     Document Type: Article

References (32)

1. Arruda, V.R., Lima, C.S., Saad, S.T. & Costa, F. (1997) Successful use of hydroxyurea in beta-thalassemia major. New England Journal of Medicine, 336, 964.
2. Atweh, G.F. & Loukopoulos, D. (2001) Pharmacological induction of fetal hemoglobin in sickle cell disease and β-thalassemia. Seminars in Hematology, 38, 367-373.
3. Bradai, M., Pissard, S., Tayeb Abad, M., Dechartres, A., Ribeil, J.A., Landais, P. & De Montalembert, M. (2007) Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion, 47, 1830-1836.
4. Calzolari, R., Pecoraro, A., Borruso, V., Troia, A., Acuto, S., Maggio, A. & Di Marzo, R. (2008) Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients. British Journal of Haematology, 141, 720-727.
5. Charache, S., Dover, G.J., Moore, R.D., Eckerts, S., Ballas, S.K., Koshy, M., Milner, P.F.A., Orringer, B.P., Phillips, G.J., Platt, O.S. & Thomas, G.H. (1992) Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood, 79, 2555-2565.
6. Cokic, V.P., Smith, R.D., Beleslin-Cokic, B.B., Njoroge, J.M., Miller, J.L., Gladwin, M.T. & Schechter, A.N. (2003) Hydroxyurea induces fetal haemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. Journal of Clinical Investigation, 11, 231-239.
7. 0 thalassemia patients. Experimental Hematology, 33, 1363-1370.
8. Dover, G.J. & Charache, S. (1992) Hydroxyurea induction of fetal hemoglobin synthesis in sickle cell disease. Seminars in Oncology, 19, 61-66.
9. Ehsani, M.A., Hedayati-Asl, A.A., Bagheri, A., Zeinali, S. & Rashidi, A. (2009) Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature. Pediatric Hematology and Oncology, 8, 560-565.
10. Fathallah, H., Sutton, M. & Atweh, G.F. (2005) Pharmacological induction of fetal haemoglobin: why haven't we been more successful in thalassemia? Annals of the New York Academy of Sciences, 1054, 228-237.
11. Fibach, E., Burke, L.P., Schechter, A.N., Noguchi, C.T. & Rodgers, G.P. (1993) Hydroxyurea increases fetal hemoglobin in cutured erythroid cells derived from normal individuals and patients with sickle cell anemia or β-thalassemia. Blood, 81, 1630-1635.
12. Fischer, K.D., Haese, A. & Nowock, J. (1993) Cooperation of GATA-1 and Sp-1 can result in synergistic transcriptional activation or interference. Journal of Biological Chemistry, 268, 23915-23923.
13. Fucharoen, S., Siritinaratkul, N., Winichagoon, P., Chawthaworn, J., Siriboon, W., Muansup, W., Chaicharoen, S., Poolsup, N., Chindavijak, B., Pootrakul, P., Piankijagum, A., Schechter, A.N. & Rodgers, G.P. (1996) Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in β-thalassemia/hemoglobin E disease. Blood, 87, 887-892.
14. Haby, C., Lisovoski, F., Aunis, D. & Zwiller, J. (1994) Stimulation of the cyclic GMP pathway by NO inducers expression of the immediate early genes c-Fos and JunB in PC12 cells. Journal of Neurochemistry, 62, 496-501.
15. Hedeker, D. & Gibbons, R.D. (1996) MIXOR: a computer program for mixed-effects ordinal regression analysis. Computer Methods and Programs in Biomedicine, 49, 157-176.
16. Hoppe, C., Vichinsky, E., Lewis, B., Foote, D. & Styles, L. (1999) Hydroxyurea and sodium phenylbutyrate in thalassemia intermedia. American Journal of Hematology, 62, 221-227.
17. Idriss, S.D., Gudi, T., Casteel, D.E., Kharitonov, V.G., Pilz, R.B. & Boss, G.R. (1999) Nitric oxide regulation of gene transcription via soluble guanylate cyclase and type I cGMP- dependent protein kinase. Journal of Biological Chemistry, 274, 9489-9493.
18. Italia, K.Y., Jijina, F.J., Merchant, R., Panjwani, S., Nadkarni, A.H., Sawant, P.M., Nair, S.B., Ghosh, K. & Colah, R.B. (2009) Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clinica Chimica Acta, 407, 10-15.
19. Karimi, M., Cohan, N., Moosavizadeh, K., Falahi, M.J. & Haghpanah, S. (2010) Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience. Pediatric Hematology and Oncology, 3, 205-211.
20. Loukopoulos, D., Voskaridou, E., Stamoulakatou, A., Papassotiriou, Y., Kalotychou, V., Loutradi, A., Cozma, G., Tsiarta, H. & Pavlides, N. (1998) Hydroxyurea therapy in thalassemia. Annals of the New York Academy of Sciences, 850, 120-128.
21. Maggio, A., Giambona, A., Cai, S.P., Wall, J., Kan, Y.W. & Chehab, F.F. (1993) Rapid and simultaneous typing of hemoglobin S, hemoglobin C, and seven Mediterranean β-thalassemia mutations by covalent reverse dot-blot analysis: application to prenatal diagnosis in Sicily. Blood, 81, 239-242.
22. Mancuso, A., Maggio, A., Renda, D., Di Marzo, R. & Rigano, P. (2006) Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. British Journal of Haematology, 133, 103-108.
23. Moi, P. & Kan, Y.W. (1990) Synergistic enhancement of globin gene expression by activator protein-1-like proteins. Proceedings of the National Academy of Sciences, 87, 9000-9004.
24. Olivieri, N.F., Rees, D.C., Ginder, G.D., Thein, S.L., Brittenham, G.M., Waye, J.S. & Weatherall, D.J. (1997) Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet, 350, 491-492.
25. Rigano, P., Manfrè, L., La Galla, R., Renda, D., Renda, M.C., Calabrese, A., Calzolari, R. & Maggio, A. (1997) Clinical and hematological response to hydroxyurea in a patient with HbLepore/β-thalassemia. Hemoglobin, 21, 219-226.
26. Safaya, S., Ibrahim, A. & Rieder, R.F. (1994) Augmentation of gamma-globin gene promoter activity by carboxylic acids and components of the human beta-globin locus control region. Blood, 84, 3929-3935.
27. Smith, R.D., Li, J., Nogouchi, C.T. & Schechter, A.N. (2000) Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood, 95, 863-868.
28. Steinberg, M.H., McCarthy, W.F., Castro, O., Ballas, S.K., Armstrong, F.D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., De Castro, L. & Waclawiw, M.A.; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematology, 85, 403-408.
29. Taher, A.T., Musallam, K.M., Karimi, M., El-Beshlawy, A., Belhoul, K., Daar, S., Saned, M.S., El-Chafic, A.H., Fasulo, M.R. & Cappellini, M.D. (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood, 115, 1886-1892.
30. Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D. & Terpos, E. (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood, 115, 2354-2363.
31. Wang, S., Wang, W., Wesley, R.A. & Danner, R.L. (1999) A Sp-1 binding site of the tumor necrosis factor alpha promoter functions as a nitric oxide response element. Journal of Biological Chemistry, 274, 33190-33193.
32. Watanapokasin, Y., Chuncharunee, S., Sanmund, D., Kongnium, W., Winichagoon, P., Rodgers, G.P. & Fucharoen, S. (2005) In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Experimental Hematology, 33, 1486-1492.